| Revision as of 19:39, 3 July 2007 editVK35 (talk | contribs)2,251 edits added mode of action, references, etc.← Previous edit | Revision as of 20:00, 3 July 2007 edit undoVK35 (talk | contribs)2,251 edits not FDA approved yetNext edit → | ||
| Line 1: | Line 1: | ||
| '''Satraplatin''' is a platinum compound that is currently under investigation for the treatment of patients with advanced prostate cancer who have failed previous chemotherapy. | '''Satraplatin''' is a platinum compound that is currently under investigation for the treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies. | ||
| The drug is taken by mouth. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPCbiotech under the name Spera. | The drug is taken by mouth. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPCbiotech under the name Spera. | ||
Revision as of 20:00, 3 July 2007
Satraplatin is a platinum compound that is currently under investigation for the treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
The drug is taken by mouth. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPCbiotech under the name Spera.
The drug has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.
References
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |